<div id="readability-page-1"><p>Benitec Biopharma ( (BNTC) ) has released its Q1 earnings. Here is a breakdown of the information Benitec Biopharma presented to its investors.</p><h3>Meet Your ETF AI Analyst</h3><ul><li> Discover how TipRanks' <i>ETF</i> AI Analyst  can help you make smarter investment decisions </li><li>   Explore ETFs TipRanks' users love  and see what insights the <b><i>ETF</i> AI Analyst</b> reveals about the ones you follow.</li></ul> <p>Benitec Biopharma Inc. is a biotechnology company specializing in the development of genetic medicines using its proprietary ‘Silence and Replace’ DNA-directed RNA interference platform, which combines RNA interference with gene therapy to target disease-causing genes. In its recent earnings report for the quarter ending September 30, 2025, Benitec Biopharma reported a net loss of $8.965 million, an increase from the $5.059 million loss in the same quarter of the previous year. The company’s operating expenses rose significantly to $9.803 million, driven by increased general and administrative costs. Despite the losses, the company maintains a strong cash position with $94.5 million in cash and cash equivalents, providing a buffer for ongoing research and development activities. Looking ahead, Benitec Biopharma remains focused on advancing its product candidates through clinical trials and exploring potential collaborations and out-licensing opportunities to support its strategic goals.</p></div>

BNTC

<p>Benitec Biopharma reported a Q1 net loss of $8.965 million, up from $5.059 million the previous year, due to increased operating expenses of $9.803 million. Despite the losses, the company holds $94.5 million in cash and remains focused on advancing clinical trials and exploring collaborations.</p>

Benitec Biopharma Reports Increased Quarterly Loss Amid Rising Expenses